Takeda engaged in antitrust scheme to delay generic constipation drug: U.S. jury
The Japan Times
A U.S. jury found Takeda liable for $885 million in damages for delaying a generic constipation drug through an anticompetitive scheme.Summary
A U.S. jury in Boston has found Japan-based Takeda Pharmaceutical liable for causing approximately $885 million in damages by delaying a generic version of its constipation drug, Amitiza, through an anticompetitive scheme. The decision came after a five-week trial where jurors sided with wholesalers, insurers, health funds, and retailers, including CVS and Walgreens, who argued that the delay forced them to overpay for the medication. The award could rise to several billion dollars, as federal antitrust law allows damages to be automatically tripled, potentially increasing the total to $2.47 billion. Takeda has denied wrongdoing and stated it will "vigorously pursue" an appeal.
(Source：The Japan Times )